<DOC>
	<DOCNO>NCT00921167</DOCNO>
	<brief_summary>To assess efficacy safety bevacizumab plus irinotecan patient recurrent anaplastic astrocytoma recurrent glioblastoma multiforme</brief_summary>
	<brief_title>A Study Evaluate Efficacy Bevacizumab Plus Irinotecan Recurrent Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically diagnose recurrent anaplastic astrocytoma recurrent glioblastoma multiforme At least 18 year age Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) criteria One measurable disease Adequate hematologic ( neutrophil count &gt; = 1500/uL , platelet &gt; = 100,000/uL ) , hepatic ( transaminase = &lt; upper normal limit ( UNL ) x2.5 , bilirubin level = &lt; UNLx1.5 , alkaline phosphatase = &lt; UNLx2.5 ) , renal ( creatinine clearance &gt; = 30mL/min ) Expected life time least 2 month A patient sign informed consent prior participation study A pregnant lactating patient A patient childbearing potential without tested pregnancy baseline positive test . ( A premenopausal woman amenorrhea period least 12 month longer consider nonchildbearing potential . ) A man woman childbearing potential without willingness use contraceptive measure study A patient history another malignant disease within past 3 year , except curatively treat basal cell carcinoma skin , cervical carcinoma situ , early gastric cancer Medically uncontrolled serious heart , lung , neurological , psychological , metabolic disease Uncontrolled serious infection Enrollment study within 30 day Hemorrhage baseline radiologic examination A patient refuse sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>